Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Jackson

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Current Drug Delivery|November 25, 2005
Lipid-based self-adjuvanting vaccinesLorena E Brown, David C Jackson
Current Protein & Peptide Science|August 19, 2007
Recent advances with TLR2-targeting lipopeptide-based vaccinesEmily M Y Eriksson, David C Jackson
Molecular Immunology|May 22, 2007
The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological functionWeiguang Zeng, Joanne Pagnon, David C Jackson
Methods in Molecular Biology (Clifton, N.J.)|August 30, 2008
Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccinesBrendon Y Chua, Weiguang Zeng, David C Jackson
Viral Immunology|January 26, 2018
Opinion: Making Inactivated and Subunit-Based Vaccines WorkBrendon Y Chua, Toshiki Sekiya, David C Jackson
Expert Review of Vaccines|October 14, 2005
Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine designAdriana Baz, David C Jackson, Norbert Kienzle, et al.
Expert Review of Vaccines|July 15, 2014
Considerations for the rapid deployment of vaccines against H7N9 influenzaBrendon Y Chua, Lorena E Brown, David C Jackson
Immunology and Cell Biology|April 1, 2009
Anti-drug vaccines to treat substance abuseBerma M Kinsey, David C Jackson, Frank M Orson
Current Drug Targets|January 24, 2004
Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategyJoseph Torresi, Mandvi Bharadwaj, David C Jackson, et al.
Frontiers in Immunology|March 14, 2014
TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious DiseaseEdin J Mifsud, Amabel C L Tan, David C Jackson
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Current Drug Delivery|November 25, 2005
Lipid-based self-adjuvanting vaccinesLorena E Brown, David C Jackson
Current Protein & Peptide Science|August 19, 2007
Recent advances with TLR2-targeting lipopeptide-based vaccinesEmily M Y Eriksson, David C Jackson
Molecular Immunology|May 22, 2007
The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological functionWeiguang Zeng, Joanne Pagnon, David C Jackson
Methods in Molecular Biology (Clifton, N.J.)|August 30, 2008
Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccinesBrendon Y Chua, Weiguang Zeng, David C Jackson
Viral Immunology|January 26, 2018
Opinion: Making Inactivated and Subunit-Based Vaccines WorkBrendon Y Chua, Toshiki Sekiya, David C Jackson
Expert Review of Vaccines|October 14, 2005
Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine designAdriana Baz, David C Jackson, Norbert Kienzle, et al.
Expert Review of Vaccines|July 15, 2014
Considerations for the rapid deployment of vaccines against H7N9 influenzaBrendon Y Chua, Lorena E Brown, David C Jackson
Immunology and Cell Biology|April 1, 2009
Anti-drug vaccines to treat substance abuseBerma M Kinsey, David C Jackson, Frank M Orson
Current Drug Targets|January 24, 2004
Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategyJoseph Torresi, Mandvi Bharadwaj, David C Jackson, et al.
Frontiers in Immunology|March 14, 2014
TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious DiseaseEdin J Mifsud, Amabel C L Tan, David C Jackson
Pageof 12